

## Jeong Mi (Jamie) Park, Pharm.D., M.S., BCTXP, FCCP, FAST

---

### **Office Address:**

Victor Vaughan Building, Room 302  
1111 Catherine Street  
Ann Arbor, MI 48109-2054

### **Contact Information:**

Phone: (734) 647-4711  
Fax: (734) 615-2314  
E-mail: jeongp@med.umich.edu

---

### **ACADEMIC POSITIONS**

- 2018 – present      Clinical Professor  
Department of Clinical Pharmacy, College of Pharmacy  
University of Michigan, Ann Arbor, MI
- 2009 – 2018        Clinical Associate Professor  
Department of Clinical Pharmacy, College of Pharmacy  
University of Michigan, Ann Arbor, MI
- 2002 – 2009        Clinical Assistant Professor  
Department of Clinical, Social, and Administrative Science, College of Pharmacy  
University of Michigan, Ann Arbor, MI
- 2001 – 2002        Adjunct Clinical Instructor  
St. Louis College of Pharmacy, St. Louis, MO

### **PROFESSIONAL POSITIONS**

- 2014 – present      Clinical Pharmacist Specialist, Transplant Endocrine Clinic  
University of Michigan Health, Ann Arbor, MI
- 2002 – present      Clinical Pharmacist Specialist, Solid Organ Transplantation  
University of Michigan Health, Ann Arbor, MI

### **EDUCATION AND POST-GRADUATE TRAINING**

- 2001 – 2002        Pharmacy Practice Residency  
Barnes-Jewish Hospital, St. Louis, MO
- 1999 – 2001        Transplantation/Immunology Fellowship  
University of Washington, Seattle, WA
- 1996 – 1999        Doctor of Pharmacy with Highest Distinction  
The University of Iowa, Iowa City, IA
- 1992 – 1994        Master of Science in Pharmacy  
Seoul National University, Seoul, South Korea
- 1988 – 1992        Bachelor of Science in Pharmacy  
Seoul National University, Seoul, South Korea

## **PROFESSIONAL LICENSURE AND CERTIFICATION**

2024 – present	Board-Certified Solid Organ Transplantation Pharmacy Specialist
2002 – present	Pharmacist, State of Michigan (License No. 5302034093)
2002 – present	Pharmacist-Controlled Substance, State of Michigan (License No. 5315170377)
2002 – 2023	Board-Certified Pharmacotherapy Specialist (Recertified in 2009 and 2016)
2001 – 2002	Pharmacist, State of Missouri (License No. 2001020938)
1999 – 2019	Pharmacist, State of Washington (License No. PH 41806)
1999 – 2002	Pharmacist, State of Iowa (License No. 19161)

## **RECOGNITIONS, HONORS AND AWARDS**

2024	Top Downloaded Article 2022, WILEY-Clinical Transplantation
2023	Making A Difference Award, University of Michigan Health (Drug Shortage)
2022, 2023	Making A Difference Award, University of Michigan Health (Teamwork)
2021	American College of Clinical Pharmacy Immunology/Transplant PRN Distinguished Investigator Award
2021	Top Cited Article 2020-2021, WILEY-Clinical Transplantation
2020	Transplant pharmacy team recognition for Outstanding COVID Response Service, Department of Pharmacy Services, University of Michigan Health
2020	Fellow of the American Society of Transplantation (FAST)
2019	Finalist for Preceptor of the Year Award, Department of Clinical Pharmacy, University of Michigan College of Pharmacy
2019	Finalist for Pharmacy Residency Preceptor of the Year Award, University of Michigan Health
2019	Third Place in the Best Paper of 2017 Award, American Society for Histocompatibility & Immunogenetics
2018	Fellow of the American College of Clinical Pharmacy (FCCP)
2018	Interprofessional Leadership Fellow, Michigan Center for Interprofessional Education
2017	Making A Difference Award, University of Michigan Health (Resident Mentoring)
2016	Poster of Distinction, 2016 American Transplant Congress
2009	Finalist for Teaching Excellence Award, University of Michigan College of Pharmacy
2007 – 2011	Honorable mention for Preceptor of the Year Award, University of Michigan College of Pharmacy

## **LEADERSHIP IN INNOVATIVE PHARMACY PRACTICE AND EDUCATION**

2023	Implementation of CYP3A5 genotype-guided tacrolimus dosing in adult kidney transplant recipients
2023	Implementation of digital medication list in adult kidney transplant recipients (A3)
2021	Interprofessional Team Pre-rounds pilot for inpatient experiential IPE
2019	Improving transitions of diabetes care in adult kidney transplant outpatients (A3)
2019	RN-managed tacrolimus protocol for adult kidney transplant outpatients
2018	Comprehensive medication review at care transitions for adult kidney transplant patients
2017	Expansion of transplant pharmacist services (2 FTE increase) <ul style="list-style-type: none"><li>• Enhanced pharmacist follow-up at acute kidney transplant clinics</li><li>• Chronic kidney transplant APP clinics (2 half-days per week)</li></ul>

- Transplant pharmacist MiChart InBasket service
  - Continuity of care for pediatric kidney and liver transplant outpatients
  - Therapeutic drug monitoring for Pediatric Nephrology service from ICU to discharge
- 2016 Implementation of IPE-STX APPE rotation
- 2015 Design and pilot of interprofessional education (IPE) to STX APPE rotation
- 2015 Development and implementation of Telephone Comprehensive Medication Review service at Transplant Specialty Pharmacy
- 2014 Development and coordination of Interdisciplinary Transplant Endocrine Clinic
- 2011 Coordinator for Pharmacy Resident Research Discussion Series (2011-2017)
- 2010 Expansion of transplant pharmacist service to transplant nephrology consult and kidney transplant clinics (1 FTE increase)
- 2009 Integration of pharmacy students into the transplant medication education workflow for Surgery Transplant inpatients (IPPE-Entrustable Professional Activity)
- 2008 Collaborative therapeutic drug monitoring and dose adjustment of calcineurin inhibitors and mTOR inhibitors for Surgery Transplant inpatients
- 2006 Expansion of transplant pharmacist service to lung transplantation and liver transplant clinics (1 FTE increase)

## **PUBLICATIONS**

### ***Peer-Reviewed Journal Articles:***

1. Lichvar A, **Park JM**, Alvey N, Feist A, Pierce DR, Fredrick S, Melaragno JI, Chandran MM, Sweiss HI, Harris M. Association between burnout and workplace climate in transplant clinical pharmacists. *American Journal of Health-System Pharmacy*. [Accepted 2024 July 8]
2. Leino AD, Takyi-Williams J, **Park JM**, Norman SP, Sun D, Farris KB, Pai MP. Clinical validation of two volumetric absorptive microsampling devices to support home-based therapeutic drug monitoring of immunosuppression after kidney transplantation. *British Journal of Clinical Pharmacology*. [Accepted 2024 July 2]
3. Mreyoud H, Walter K, Wilpula E, **Park JM**. The efficacy and safety of SGLT2-inhibitors in solid organ transplant recipients: a scoping review. *Pharmacotherapy*. 2024;44:444-466. doi: 10.1002/phar.2928 [Epub 2024 May 21]
4. Leino AD, Magee JC, Kershaw DB, Pai MP, **Park JM**. A comprehensive mixed-method approach to characterize the source of diurnal tacrolimus exposure variability in children. *The Journal of Clinical Pharmacology*. 2024;64(3):334-344.
5. Lawrence SE, Chandran MM, **Park JM**, Sweiss H, Jensen T, Choksi P, Crowther B. Sweet and simple as syrup: A review and guidance for use of novel antihyperglycemic agents for post-transplant diabetes mellitus and type II diabetes after kidney transplantation. [Invited Review] *Clinical Transplantation*. 2023;37(3):e14922. doi: 10.1111/ctr.14922 [Epub 2023 Jan 28]
6. Pasternak AL, **Park JM**, Pai M. Predictive capacity of population pharmacokinetic models for the tacrolimus dose requirements of pediatric solid organ transplant recipients. *Therapeutic Drug Monitoring*. 2023;45(1):95-101. doi: 10.1097/FTD.0000000000001002 [Epub 2022 June 27]

7. Szczepanik A, Choi D, Brady B, Chandran M, Diamond A, Do V, Frederick S, Kaiser T, Khalil K, Laub MR, Leino AD, **Park JM**, Pierce DR, Rendulic T, Wiegel JJ, Fose J, Jorgenson MR. The use of non-transplant biologics in solid organ transplant recipients: A practical review for the frontline clinician. *Clinical Transplantation*. 2022;36(7):e14743. doi:10.1111/ctr.14743 [Epub 2022 June 12] \*\*\* **Top Downloaded Article 2022, WILEY-Clinical Transplantation**
8. Ky TQ, Norman SP, Taylor RM, Barakat AO, Harb R, Laviste NC, **Park JM**. Evaluation of a standardized tacrolimus therapeutic drug monitoring protocol in stable renal transplant recipients. *Progress in Transplantation*. 2022;32(3):212-218. [Epub 2022 Jun 12]
9. Hanigan S, **Park JM**. Evaluating pharmacokinetic drug-drug interactions of direct acting oral anticoagulants based on patient renal function. *Expert Opinion on Drug Metabolism and Toxicology*. 2022;18(3):189-202. doi: 10.1080/17425255.2022.2074397. [Epub 2022 May 17] \*\*\***Invited review**
10. Aide SK, Bitar A, Konerman MC, Dorsch MP, Andrews C, Pogue K, **Park JM**. Tacrolimus time in therapeutic range and long-term outcomes in heart transplant recipients. *Pharmacotherapy*. 2022;42(2):106-111. doi:10.1002/phar.2653. [Epub 2021 Dec 9]
11. Shaikh SA, Kahn J, Aksentijevic A, Kawewat-Ho P, Bixby A, Rendulic T, **Park JM**. A multicenter evaluation of hepatitis B reactivation with and without antiviral prophylaxis after kidney transplantation. *Transplant Infectious Disease*. 2022;24(1):e1375. doi:10.1111/tid.13751. [Epub 2021 Nov 1]
12. Schumacher L, Fang F, Kidwell KM, Shakeel F, Hertz DL, **Park JM**, Pasternak AL. *SLCO1B3* polymorphisms and clinical outcomes in kidney transplant recipients. *Pharmacogenomics*. 2021;22(17):1111-1120. [Epub 2021 Oct 6]
13. Bixby AL, Fitzgerald L, **Park JM**, Kaul D, Tischer S. Comparison of standard vs. low dose valganciclovir regimens for cytomegalovirus prophylaxis in high-risk liver transplant recipients. *Transplant Infectious Disease*. 2021;23(5):e13713. doi:10.1111/tid.13713. [Epub 2021 Aug 24]
14. Lichvar AB, Chandran MM, Do V, Rendulic T, Szczepanik A, Pierce DR, **Park JM**. Entrustable professional activities for pharmacy students: a primer for solid organ transplant preceptors. *American Journal of Health-System Pharmacy*. 2021;78(24):2225-2235. doi:10.1093/ajhp/zxab320. [Epub 2021 Aug 5]
15. Leino AD, **Park JM**, Pasternak AL. Impact of CYP3A5 phenotype on time in therapeutic range and clinical outcomes in pediatric renal and heart transplant recipients. *Pharmacotherapy*. 2021;41(8):649-657. doi:10.1002/phar.2601. [Epub 2021 June 15]
16. Jorgenson MR, Descourouez JL, Brady BL, Chandran MM, Do V, Kim M, Laub MR, Lichvar A, **Park JM**, Szczepanik A, Alloway RR. A call for transplant stewardship: the need for expanded evidence-based evaluation of induction and biologic based cost savings strategies in kidney transplantation and beyond. *Clinical Transplantation*. 2021;35(9):e14372. doi:10.1111/ctr.14372. [Epub 2021 May 25]
17. Pasternak AL, Marshall VD, Gersch CL, Rae JM, Englesbe M, **Park JM**. Evaluating the impact of CYP3A5 genotype on post-transplant healthcare resource utilization in pediatric renal and heart

transplant recipients receiving tacrolimus. *Pharmacogenomics and Personalized Medicine* 2021;14:319-326. doi:10.2147/PGM.S285444. [Epub 2021 Mar 12]

18. Ky TQ, **Park JM**, McMurry KA, Tischer SM, Fitzgerald LJ, Cotiguala L. Oropharyngeal candidiasis outcomes in renal transplant recipients receiving nystatin versus no antifungal prophylaxis. *Transplant Infectious Disease*. 2021;23(3):e13559. doi:10.1111/tid.13559. [Epub 2021 Jan 19]
19. Cotiguala L, Masood A, **Park JM**, Samaniego-Picota MD, Kaul D, Naik AS. Increasing net immunosuppression after BK polyoma virus infection. *Transplant Infectious Disease*. 2021;23(2):e13472. doi:10.1111/tid.13472. [Epub 2020 Sep 22]
20. Anderson S, Cotiguala L, Tischer S, **Park JM**, McMurry KA. Review of newer antidiabetic agents for diabetes management in kidney transplant recipients. *The Annals of Pharmacotherapy*. 2021;55(4):496-508. [Epub 2020 Aug 14]
21. Melaragno JI, Bowman LJ, **Park JM**, Lourenco LM, Doligalski CT, Brady BL, Descourouez JL, Chandran MM, Nickels MW, Page II RL. The clinical conundrum of cannabis: current practices and recommendations for transplant clinicians: an opinion of the Immunology/Transplantation PRN of the American College of Clinical Pharmacy. *Transplantation*. 2021;105(2):291-299. [Epub 2020 May 11]
22. C4 Article: Implications of COVID-19 in Transplantation. *American Journal of Transplantation*. 2021;21(5):1801-1815. doi:10.1111/ajt.16346. [Epub 2020 Nov 6] **\*\*\*Served as a contributor**
23. Bixby AL, Lichvar AB, Salerno D, **Park JM**. Use of direct-acting oral anticoagulants in solid organ transplantation: A systematic review. *Pharmacotherapy*. 2021;41(1):28-43. [Epub 2020 Nov 6] **\*\*\*Invited review for a special theme issue on solid organ transplantation**
24. Schumacher L, Leino AD, **Park JM**. Tacrolimus inpatient variability in solid organ transplantation: a multiorgan perspective. *Pharmacotherapy*. 2021;41(1):103-118. [Epub 2020 Nov 1] **\*\*\*Published in a special theme issue on solid organ transplantation**
25. Pilch NA, **Park JM**, Lichvar A, Kane C, Bowman L, Melaragno JI, Sobhanian M, Perez C, Trofe-Clark J, Fleming JN. Observation from a systematic review of pharmacist-led research in solid organ transplant: an opinion paper of the ACCP Immunology/Transplantation Practice and Research Network. *Journal of the American College of Clinical Pharmacy*. 2020;3:1344-1354. doi: 10.1002/jac5.1294. [Epub 2020 July 2]
26. Jorgenson M, Descourouez J, Brady B, Bowman L, Hammad S, Kaiser, T, Laub M, Melaragno JI, **Park JM**, Chandran M. Alternatives to immediate release tacrolimus in solid organ transplant recipients: when the gold standard is in short supply. *Clinical Transplantation*. 2020;34(7):e13903. doi: 10.1111/ctr.13903. [Epub 2020 May 29]
27. Lichvar AB, Pierce DR, Salerno D, Klem P, Waldman G, **Park JM**. Utilization of direct acting oral anticoagulation in solid organ transplant patients: a national survey of institutional practices. *Clinical Transplantation*. 2020;34(6):e13853. doi:10.1111/ctr.13853. [Epub 2020 April 6] **\*\*\*WILEY Top Cited Article 2020-2021**

28. Bixby AL, Shaikh SA, Naik AS, Cotiguala L, McMurry K, Samaniego-Picota MD, Marshall VD, **Park JM**. Safety and efficacy of direct-acting oral anticoagulants versus warfarin in kidney transplant recipients: a retrospective single center cohort study. *Transplant International*. 2020;33(7):740-751.
29. C4 Article: Challenges and Solutions to Appropriate and Timely Medication Access in Transplantation in the U.S. *American Journal of Transplantation*. 2020;20(2):362-376. **\*\*\*Served as a section editor and contributor**
30. Sharma P, Sun Y, Neal J, Erley J, Shen J, Tischer S, Sonnenday C, **Park JM**. Renal outcomes of liver transplantation recipients receiving standard immunosuppression and early renal sparing immunosuppression: a retrospective single-center study. *Transplantation Direct*. 2019;5(9):e480. doi: 10.1097/TXD.0000000000000917.
31. Leek RB, **Park JM**, Koerschner C, Mawby J, Sonnenday CJ, Wright Nunes JA, Sharma P. Novel educational and goal-setting tool to improve knowledge of chronic kidney disease among liver transplant recipients: a pilot study. *PLoS ONE*. 2019;14(7):e0219856. doi: 10.1371/journal.pone.0219856.
32. Pasternak AL, Kidwell KM, Dempsey JM, Gersch CL, Pesch A, Sun Y, Rae JM, Hertz DL, **Park JM**. Impact of CYP3A5 phenotype on tacrolimus concentrations after sublingual and oral administration in lung transplant. *Pharmacogenomics*. 2019;20(6):421-432.
33. Helmuth ME, Liu Q, Turenne MN, **Park JM**, Oguntimein M, Dutcher SK, Balkrishnan R, Sharma P, Zee J, Leichtman AB, Smith AR. Secular trends in the cost of immunosuppressants after solid organ transplantation in the United States. *Clinical Journal of American Society of Nephrology*. 2019;14(3):421-430.
34. Shaikh S, Jasiak-Panek N, **Park JM**. A national survey of valganciclovir dosing strategies in pediatric organ transplant recipients. *Clinical Transplantation*. 2018;32(9):e13369. doi:10.1111/ctr.13369.
35. **Park JM**, Koerschner C, Mawby J, Selman S, Kwon HK, Sonnenday CJ, Wright Nunes JA, Sharma P. Knowledge of chronic kidney disease among liver transplant recipients. *Liver Transplantation*. 2018; 24(9):1288-1292.
36. Liu Q, Smith AR, **Park JM**, Oguntimein M, Dutcher S, Bello G, Helmuth M, Turenne M, Balkrishnan R, Fava M, Beil CA, Saulles A, Goel S, Sharma P, Leichtman A, Zee J. The adoption of generic immunosuppressant medications for kidney, liver, and heart transplantation among recipients in Colorado or nationally with Medicare Part D. *American Journal of Transplantation*. 2018;18(7):1764-1773.
37. Ramon DS, Huang Y, Zhao L, Rendulic T, **Park JM**, Sung RS, Samaniego M. Use of complement binding assays to assess the efficacy of antibody mediated rejection therapy and prediction of graft survival in kidney transplantation. *Human Immunology*. 2017;78(2):57-63. **\*\*\*Third Place in the Best Paper of 2017 Award by American Society for Histocompatibility & Immunogenetics**
38. Wang XX, Liu W, Zheng T, **Park JM**, Smith DE, Feng MR. Population pharmacokinetics of mycophenolic acid and its glucuronide metabolite in lung transplant recipients with and without cystic fibrosis. *Xenobiotica*. 2017;47(8):697-704.

39. Heldenbrand S, Li C, Cross RP, DePiero KA, Dick TB, Ferguson K, Kim M, Newkirk E, **Park JM**, Sudaria-Kerr J, Tichy EM, Ueda KR, Weng R, Wisniewski J, Gabardi S. Multicenter evaluation of efficacy and safety of low-dose vs. high-dose valganciclovir for prevention of CMV disease in donor and recipient positive (D+/R+) renal transplant recipients. *Transplant Infectious Disease*. 2016;18(6):904-912.
40. Early C, **Park J**, Dorsch M, Pogue K, Aaronson K, Hanigan S. Effect of metronidazole use on tacrolimus concentrations in transplant patients treated for *Clostridium difficile*. *Transplant Infectious Disease*. 2016;18(5):714-720.
41. Jasiak NM, **Park JM**. Immunosuppression in solid-organ transplantation: essentials and practical tips. *Critical Care Nursing Quarterly*. 2016;39(3):227-240.
42. Pennington CA, Tischer SM, Lee E, Lee S, Sindelar Jr. J, **Park JM**. Evaluation of a weight-based rabbit anti-thymocyte globulin induction dosing regimen for kidney transplant recipients. *Pharmacotherapy*. 2015;35(8):748-754.
43. Wang XX, Feng MR, Nguyen H, Smith DE, Cibrik DM, **Park JM**. Population pharmacokinetics of mycophenolic acid in lung transplant recipients with and without cystic fibrosis. *European Journal of Clinical Pharmacology*. 2015;71(6):673-679.
44. Pennington CA, **Park JM**. Sublingual tacrolimus as an alternative to oral administration for solid organ transplant recipients. *American Journal of Health-System Pharmacy*. 2015;72(4):277-284.
45. Rendulic T, Ramon DS, Killen PD, Samaniego-Picota M, **Park JM**. Beyond criteria and definitions: outcomes of a standardized antibody-mediated rejection protocol with a diagnostic schema different from the Banff 2009 criteria. *Clinical Transplants*. 2014:179-187.
46. Stuckey L, Clark Ojo R, **Park JM**, Annesley T, Bartos C, Cibrik DM. Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis. *Therapeutic Drug Monitoring*. 2014;36(2):148-151.
47. Yu MA, **Park JM**. Valganciclovir: therapeutic role in pediatric solid organ transplant recipients. *Expert Opinion on Pharmacotherapy*. 2013;14(6):807-815. \*\*\*Invited review
48. Luan FL, Samaniego M, **Park JM**, Ojo A. Choice of induction regimens on the risk of cytomegalovirus infection in donor positive and recipient negative kidney transplant recipients. *Transplant Infectious Disease*. 2010;12(6):473-479.
49. Ranney DN, Englesbe MJ, Muhammad W, Al-Holou SN, **Park JM**, Pelletier SJ, Punch JD, Lynch RJ. Should heart, lung, and liver transplant recipients receive immunosuppression induction for kidney transplantation? *Clinical Transplantation*. 2010;24(1):67-72.
50. Miller JT, Collins CD, Stuckey LJ, Luan FL, Englesbe MJ, Magee JC, **Park JM**. Clinical and economic outcomes of rabbit antithymocyte globulin induction in adults who received kidney transplants from living unrelated donors and received cyclosporine-based immunosuppression. *Pharmacotherapy*. 2009;29(10):1166-1174.

51. Luan FL, Stuckey LJ, **Park JM**, Kaul D, Cibrik DM, Ojo A. Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection. *Journal of American Society of Nephrology*. 2009;20(11):2449-2458.
52. **Park JM**, Lake KD, Cibrik DM. Impact of changing from cyclosporine to tacrolimus on pharmacokinetics of mycophenolic acid in diabetic renal transplant recipients. *Therapeutic Drug Monitoring*. 2008;30(5):591-596.
53. Gelone DK, **Park JM**, Lake KD. Lack of effect of oral iron administration on mycophenolic acid pharmacokinetics in stable renal transplant recipients. *Pharmacotherapy*. 2007;27(9):1272-1278.
54. Luan FL, Chopra P, **Park JM**, Norman SP, Cibrik DM, Ojo AK. Efficacy of valganciclovir in the treatment of cytomegalovirus disease in kidney and pancreas transplant recipients. *Transplantation Proceedings*. 2006;38(10):3673-3675.
55. **Park JM**, Lake KD, Arenas JD, Fontana RJ. Efficacy and safety of low-dose valganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients. *Liver Transplantation*. 2006;12(1):112-116.
56. **Park JM**, Luan FL. Management of hypertension in solid organ transplantation. *Progress in Transplantation*. 2005;15(1):17-22.
57. Chiu LM, Domagala BM, **Park JM**. Management of opportunistic infections in solid organ transplantation. *Progress in Transplantation*. 2004;14(2):114-129.
58. Prescott Jr. WA, Callahan BL, **Park JM**. Tacrolimus toxicity associated with concomitant metoclopramide therapy. *Pharmacotherapy*. 2004;24(4):522-527.
59. Hardinger KL, **Park JM**, Schnitzler MA, Koch M, Miller BW, Brennan DC. Pharmacokinetics of tacrolimus in kidney transplant recipients: twice daily versus once daily dosing. *American Journal of Transplantation*. 2004;4(4):621-625.
60. Hebert MF, **Park JM**, Chen YL, Akhtar S, Larson AM. Effects of St. John's wort (*Hypericum perforatum*) on tacrolimus pharmacokinetics in healthy volunteers. *The Journal of Clinical Pharmacology*. 2004;44(1):89-94.
61. **Park JM**, Lin YS, Calamia JC, Thummel KE, Slattery JT, Kalhorn TF, Carithers Jr. RL, Levy AE, Marsh CL, Hebert MF. Transiently altered acetaminophen metabolism after liver transplantation. *Clinical Pharmacology & Therapeutics*. 2003;73(6):545-553.
62. **Park JM**, Moon CH, Lee MG. Pharmacokinetic changes of methotrexate after intravenous administration to uranyl nitrate-induced acute renal failure rats. *Research Communications in Molecular Pathology & Pharmacology*. 1996;93(3):353-362.
63. **Park JM**, Moon CH, Lee MG. Pharmacokinetic changes of methotrexate after intravenous administration to streptozotocin-induced diabetes mellitus rats. *Research Communications in Molecular Pathology & Pharmacology*. 1996;93(3):343-352.



64. Hwang SJ, **Park JM**, Lee WI, Kim ON, Lee MG. The effect of water deprivation on the pharmacokinetics of methotrexate in rats. *Biopharmaceutics & Drug Disposition*. 1995;16(3):245-250.
65. **Park JM**, Ahn BN, Yoon EJ, Lee MG, Shim CK, Kim CK. The pharmacokinetics of methotrexate after intravenous administration of methotrexate-loaded proliposomes to rats. *Biopharmaceutics & Drug Disposition*. 1994;15(5):391-407.
66. Yoon WH, Yoon EJ, Jang SH, Lee SH, Lee HJ, **Park JM**, Choi KE, Lee MG. Pharmacokinetics of ciprofloxacin after intravenous administration of ciprofloxacin-TOF in rabbits. *International Journal of Pharmaceutics*. 1994;102(1-3):249-255.

#### **Book Chapters:**

1. **Park JM**, Shaikh S. Chapter 17. Solid Organ Transplantation. In: Sutton SS, ed. NAPLEX Review Guide, 4<sup>th</sup> ed. New York, NY: McGraw-Hill, 2021. <https://accesspharmacy.mhmedical.com/NAPLEX.aspx>
2. **Park JM**, Jasiak NM. Chapter 17. Solid Organ Transplantation. In: Sutton SS, ed. NAPLEX Review Guide, 3<sup>rd</sup> ed. New York, NY: McGraw-Hill, 2018:158-165.
3. **Park JM**. Chapter 19. Solid Organ Transplantation. In: Sutton SS, ed. NAPLEX Review Guide, 2<sup>nd</sup> ed. New York, NY: McGraw-Hill; 2015:163-170.
4. **Park JM**, Jorgenson MR. Chapter 18. Solid Organ Transplantation. In: Sutton SS, ed. NAPLEX Review Guide. New York, NY: McGraw-Hill; 2011:151-158.

#### **Letters to the Editor, Book Reviews and Newsletters:**

1. New IPE Pilot for Pharmacy and Medical Student Inpatient Pre-Rounds. *Michigan Center for Interprofessional Education*. Available at: <https://interprofessional.umich.edu/2021/02/02/new-ipe-pilot-for-pharmacy-and-medical-student-inpatient-pre-rounds/>. Accessed February 2, 2021.
2. Transplant Endocrine Clinic Celebrates First Anniversary: Highlights Contributions of Pharmacist in Interprofessional Practice. *University of Michigan College of Pharmacy News & Announcements*. Available at: <https://pharmacy.umich.edu/about-college/news/category/faculty-news/transplant-endocrine-clinic-celebrates-first-anniversary-highlights-contributions-pharmacist-interprofessional-practice>. Accessed October 1, 2015.
3. **Park JM**, Lake KD, Fontana RJ. Valganciclovir for cytomegalovirus prophylaxis in liver transplant recipients [letter]. *Liver Transplantation* 2006;12:1022-1023.
4. **Park JM**. Herbal-Drug Interactions and Adverse Effects: An Evidence-Base Quick Reference Guide by Richard B. Philp [book review]. *Journal of Pharmacy Technology* 2004;20:359.
5. Salley MA, **Park JM**. Immunosuppression – What is it? Why is it needed? What does it do? *University of Michigan Transplant Center Newsletter*. Fall 2006. Available at: [http://www.med.umich.edu/trans/public/pdf/TCNews\\_Fall06.pdf](http://www.med.umich.edu/trans/public/pdf/TCNews_Fall06.pdf). Accessed December 1, 2006.

**Peer-reviewed Collaborative Practice Guidelines and Patient Education Materials:**

1. University of Michigan Transplant Center Clinical Protocols for Adult Kidney, Liver, and Pancreas Transplant Programs (with ongoing periodic reviews and updates)
  - Immunosuppression
  - Rejection
  - Infection prophylaxis and treatment
  - Pre-operative and postoperative orders
  - Desensitization
  - Recurrent focal segmental glomerulosclerosis
  - Hypertension management
  - Lipid management
  - Post-transplant anemia management
  - Bone and mineral disease management
  - Diabetes management
  - Management of biologics
  - IV contrast hypersensitivity/nephropathy
  - Management of combined liver/kidney transplant
  - Procedure for kidney biopsy in Transplant ACU
  - Management of hepatitis B in kidney transplant donors and recipients
2. University of Michigan Transplant Center Clinical Protocols for Pediatric Kidney and Liver Transplant Programs (with ongoing periodic reviews and updates)
  - Immunosuppression
  - Rejection
  - Infection prophylaxis and treatment
  - Pre-operative and postoperative orders
  - Management of pediatric kidney transplant recipients with angiotensin II type-1 receptor antibody
3. University of Michigan Transplant Center Patient Education Guides for Pediatric Liver Transplant 2016 (Medications chapter)
4. University of Michigan Transplant Center Patient Education Guides for Pediatric Kidney Transplant 2015 and 2018 (Medications chapter)
5. University of Michigan Transplant Center Patient Education Guides for Kidney, Pancreas, and Liver Transplant 2014 (Medications chapter)
6. University of Michigan Health System Antimicrobial Use Guidelines 2005
  - Treatment of *Aspergillus* infection in non-BMT and non-Hem/Onc patients
  - Review of antiviral agents

**Abstracts:**

1. Lichvar A, **Park J**, Alvey N, Feist A, Pierce D, Fredrick S, Melaragno J, Chandran M, Harris M. Association between burnout and workplace climate in transplant clinical pharmacists. *American*

*Journal of Transplantation* 2024;24(s6):S367-368. [Rapid Fire Oral Abstract presentation by A Lichvar at 2024 American Transplant Congress – Philadelphia, PA, June 1-5, 2024]

2. Chen A, Hagopian J, **Park J**, Walter K, Mreyoud H, Doshi M, Wilpula E. The impact of mycophenolate stewardship on infectious complications in elderly kidney transplant recipients. *American Journal of Transplantation* 2024;24(s6):S778.
3. Walter K, **Park J**, Papaleontiou M, Low Wang C, Gumber R, Choksi P. Utilization of sodium-glucose cotransporter 2 inhibitors in adult kidney transplant recipients: a survey of endocrinology and nephrology provider. *American Journal of Transplantation* 2024;24(s6):S949.
4. Chau MP, Hagopian JC, Marshall VD, **Park JM**. Extended-release tacrolimus and kidney function in *de novo* liver transplant recipients. *American Journal of Transplantation* 2024;24(s6):S966-967.
5. Elmasri AF, **Park JM**, Fitzgerald L, McMurry K, Patil S, Fritsche LG, Pasternak AL. Impact of CYP3A5 genotype and cystic fibrosis on extended-release tacrolimus (LCPT) exposure in lung transplant recipients. *Pharmacogenetics and Genomics*. 2023;33(8):199-200.
6. Mreyoud H, Fitzgerald L, **Park J**, Wilpula E, Belloli E, Walter K. Assessment of antimetabolite intolerance in older lung transplant recipients. *American Journal of Transplantation* 2023;23(s6):S387. [Rapid Fire Oral Abstract presentation by H Mreyoud at 2023 American Transplant Congress – San Diego, CA, June 3-7, 2023]
7. Walter K, Mreyoud H, Wilpula E, **Park J**. A pharmacist survey of utilization of sodium-glucose cotransporter-2 inhibitors in solid organ transplant recipients. *American Journal of Transplantation* 2023;23(s6):S944.
8. Sharkey J, McMurry K, **Park J**, Carlson C, Gregg K, Kaul D, Lyu D, Fitzgerald L. Evaluating *Pneumocystis jiroveci* pneumonia prophylaxis in lung transplant recipients. *American Journal of Transplantation* 2021;21(s3). <https://atcmeetingabstracts.com/abstract/evaluating-pneumocystis-jiroveci-pneumonia-prophylaxis-in-lung-transplant-recipients/>. Accessed June 8, 2021 [Rapid Fire Oral Abstract presentation by J Sharkey at American Transplant Congress 2021 Virtual Connect, June 7, 2021]
9. Ky TQ, Cotiguala L, Fitzgerald, L, McMurry K, **Park J**, Tischer S. Comparison of oropharyngeal candidiasis outcomes in renal transplant recipients receiving nystatin or no antifungal prophylaxis. *American Journal of Transplantation* 2020;20(s3). <https://atcmeetingabstracts.com/abstract/comparison-of-oropharyngeal-candidiasis-outcomes-in-renal-transplant-recipients-receiving-nystatin-or-no-antifungal-prophylaxis/>. Accessed June 11, 2020. [Platform presentation by TQ Ky at 2020 Virtual American Transplant Congress, May 30, 2020]
10. Bixby AL, Shaikh SA, Naik AS, Cotiguala L, McMurry K, Samaniego-Picota MD, Marshall VD, **Park JM**. Safety and efficacy of direct-acting oral anticoagulants versus warfarin in kidney transplant recipients. *American Journal of Transplantation* 2020;20(s3). <https://atcmeetingabstracts.com/abstract/safety-and-efficacy-of-direct-acting-oral-anticoagulants-versus-warfarin-in-kidney-transplant-recipients/>. Accessed June 11, 2020.

11. Pierce D, Lichvar A, Waldman G, Salerno D, Klem P, **Park J**. Utilization of direct acting oral anticoagulation in solid organ transplant patients: A national survey of institutional practices. *American Journal of Transplantation* 2020. <https://atcmeetingabstracts.com/abstract/utilization-of-direct-acting-oral-anticoagulation-in-solid-organ-transplant-patients-a-national-survey-of-institutional-practices/>. Accessed June 11, 2020.
12. Sharma P, Tischer S, Kwon H, Sonnenday C, **Park JM**. Post transplant renal outcomes among liver transplant recipients with preserved renal function. *Gastroenterology* 2020;158(6s1):S-1339.
13. Bixby AL, Fitzgerald L, Cotiguala C, **Park JM**, Kaul D, Sonnenday C, Tischer S. Comparison of two dosing regimens of valganciclovir for cytomegalovirus prophylaxis in high-risk liver transplant recipients. *American Journal of Transplantation* 2019;19(s3):720-721.
14. Gabriel J, Shaikh S, **Park J**, Tischer S, Kaul D, Patel T. The impact of antibiotic therapy on clinical outcomes in kidney transplant recipients with asymptomatic bacteriuria. *American Journal of Transplantation* 2019;19(s3):517-518. [Platform presentation by S. Shaikh at 2019 American Transplant Congress – Boston, MA, June 1-5, 2019]
15. Cotiguala L, Masood A, **Park J**, Naik A. Increasing net immunosuppression after BK viremia. *American Journal of Transplantation* 2019;19(s3):547-548. [Platform presentation by L Cotiguala at 2019 American Transplant Congress – Boston, MA, June 1-5, 2019]
16. Sharma P, Sun Y, Neal J, Erley J, Shen J, Tischer S, Sonnenday C, **Park J**. Renal-sparing immunosuppression at time of transplant does not improve post-transplant renal outcomes. *Hepatology* 2018;68(S1):78A.
17. Shaikh S, Samaniego M, **Park J**. Direct oral anticoagulation use in kidney transplant recipients. *American Journal of Transplantation* 2018;18(s4):549.
18. Lu Y, Lyons J, Tischer S, Woodside K, **Park J**. Efficacy and safety of a single-dose rituximab for prevention of focal segmental glomerulosclerosis recurrence after kidney transplant. *American Journal of Transplantation* 2018;18(s4):801.
19. Shaikh S, Panek N, **Park J**. A national survey of valganciclovir dosing strategies in pediatric solid organ transplant recipients. *American Journal of Transplantation* 2018;18(s4):889.
20. Leek R, **Park J**, Koerschner C, Mawby J, Wright Nunes J, Sonnenday C, Sharma P. Assessment of a novel chronic kidney disease educational and goal setting tool among liver transplant recipients. *American Journal of Transplantation* 2018;18(s4):962.
21. Pasternak AL, Kidwell K, Dempsey J, Sun Y, Hertz DL, **Park JM**. The impact of CYP3A5 genotype on tacrolimus trough concentrations varies between routes of administration. *Clinical Pharmacology & Therapeutics* 2018;103(s1):s46-s47.
22. **Park J**, Koerschner C, Selman S, Mawby J, Paknikar S, Sonnenday C, Wright Nunes J, Sharma P. Knowledge of chronic kidney disease among liver transplant patients. *American Journal of Transplantation* 2017;17(s3):774-775.

23. Helmuth M, Turenne M, **Park J**, Liu Q, Oguntimein M, Dutcher S, Balkrishnan R, Zee J, Smith A, Leichtman A. Immunosuppressant costs for Medicare Part D and kidney transplant recipients since the introduction of generic formulations in an incident kidney transplant population. *American Journal of Transplantation* 2017;17(s3):564-565.
24. Liu Q, Smith A, **Park J**, Oguntimein M, Dutcher S, Bello G, Helmuth M, Turenne M, Balkrishnan R, Fava M, Sharma P, Beil C, Leichtman A, Zee J. The adoption of generic immunosuppressant medications among kidney and liver transplant recipients using the Colorado all payer claims database. *American Journal of Transplantation* 2017;17(s3):564.
25. James C, Woodside K, **Park J**, Naik A, Farkash E, Sung R, Samaniego M, Huang Y. Short term renal allograft outcomes following treatment of early subclinical borderline changes on surveillance biopsies. *American Journal of Transplantation* 2017;17(s3):557-558.
26. **Park J**, Trofe-Clark J, Kaiser T, Pilch N, Taber D. Association between provision of transplant pharmacy services and center-level patient and graft outcomes in U.S. adult kidney transplant programs. *American Journal of Transplantation* 2017;17(s3):501.
27. Zee J, Bello GA, Oguntimein M, Beil CA, Liu Q, **Park J**, Saulles AR, Goel A, Balkrishnam R, Fava M, Merion RM, Leichtman AB, Sharma P. Comparison of the effects of brand name versus generic immunosuppressants on long-term graft failure risk among U.S. liver transplant recipients: analysis of SRTR and Medicare claims data. *Transplantation* 2016;100(7S):S352. [Oral presentation by J. Zee at the 26th International Congress of The Transplant Society - Hong Kong, China, August 18-23, 2016]
28. Zee J, Bello GA, Oguntimein M, Beil CA, Liu Q, **Park J**, Saulles AR, Goel A, Balkrishnam R, Fava M, Sharma P, Merion RM, Leichtman AB. Comparison of the effects of brand name versus generic immunosuppressants on long-term graft failure risk among U.S. kidney transplant recipients: analysis of SRTR and Medicare claims data. *Transplantation* 2016;100(7S):S400. [Platform presentation by J. Zee at the 26th International Congress of The Transplant Society - Hong Kong, China, August 18-23, 2016]
29. Neal J, Sun Y, Erley J, Shen J, Sonnenday C, Sharma P, **Park JM**. Renal risk index and acute kidney injury in liver transplant patients. *American Journal of Transplantation* 2016;16(s3):556-557.
30. Huang Y, **Park JM**, Naik A, Kaul D. Standard dose valganciclovir prophylaxis for high-risk kidney transplant recipients reduces incidences of breakthrough and resistant cytomegalovirus infection. *American Journal of Transplantation* 2016;16(s3):777.
31. Palumbo A, Kelly L, **Park JM**. Transitions of care to reduce early readmissions following kidney transplantation. *American Journal of Transplantation* 2013;13(s5):436.
32. Tischer S, **Park JM**, Stuckey L, Sonnenday C, Fontana R. Incidence of CMV disease in high-risk liver transplant recipients on low dose valganciclovir prophylaxis. *American Journal of Transplantation* 2013;13(s5):221.
33. Gabardi S, Cross R, DePiero K, Dick T, Ferguson K, Newkirk E, **Park JM**, Tichy E, Ueda K, Weng R, Heldenbrand S. Prevention of cytomegalovirus with valganciclovir 450 mg daily vs. 900 mg daily in

intermediate risk renal transplant recipients (D-/R+): a multicenter safety and efficacy evaluation. *American Journal of Transplantation* 2013;13(s5):210.

34. Gabardi S, Cross R, DePiero K, Dick T, Maldonado A, Maxwell P, Nelson J, **Park JM**, Ueda K, Weng RR, Newkirk E. Efficacy and safety of 3 vs. 6 months of low-dose valganciclovir for prevention of cytomegalovirus disease in moderate-risk (D+/R+) renal transplant recipients receiving antilymphocyte antibody induction therapy. *American Journal of Transplantation* 2013;13(s5):56.
35. Gabardi S, Cross R, DePiero K, Dick T, Ferguson K, Newkirk E, **Park JM**, Tichy E, Ueda K, Weng R, Heldenbrand S. Multicenter evaluation of efficacy and safety of valganciclovir 450 mg/day vs. 900 mg/day for prevention of cytomegalovirus disease in donor and recipient positive (D+/R+) renal transplant recipients. *American Journal of Transplantation* 2013;13(s5):56.
36. Horwedel TA, Huang Y, **Park JM**. Low tacrolimus levels in the first week are associated with rejection in kidney transplant patient receiving antithymocyte globulin induction. *American Journal of Transplantation* 2012;12(s3):323.
37. Gabardi S, Cross RP, DePiero KA, Dick TB, Maxwell P, Nelson J, Newkirk E, Nguyen K, **Park JM**, Tichy E, Ueda KR, Weng RR, Maldonado AQ. Efficacy and safety of 3 vs. 6 months of low-dose valganciclovir for prevention of cytomegalovirus disease in moderate-risk (D-/R+) renal transplant recipients receiving antilymphocyte antibody induction therapy. *American Journal of Transplantation* 2012;12(s3):467.
38. Luan FL, Kommareddi M, **Park JM**, Ojo A. Impact of cytomegalovirus infection in D+/R- kidney transplant patients receiving six month low dose valganciclovir. *American Journal of Transplantation* 2011;11(s2):42.
39. Stuckey LJ, Ojo TC, **Park JM**, Annesley TM, Bartos CE, Cibrik DM. Pharmacokinetics of mycophenolic acid in cystic fibrosis lung transplant recipients. *American Journal of Transplantation* 2011;11(s2):414.
40. Luan FL, Stuckey LJ, **Park JM**, Ojo A. Economic analysis of extended cytomegalovirus prophylaxis in high risk kidney transplant patients. *American Journal of Transplantation* 2009;9(s2):250.
41. **Park JM**, Figurski MJ, Shaw LM. Valganciclovir does not affect the steady-state pharmacokinetics of mycophenolic acid and its glucuronide metabolites. *American Journal of Transplantation* 2008;8(s2):525.
42. Stuckey LJ, **Park JM**, Luan FL. Impact of extended CMV prophylaxis in adult renal transplant recipients at high risk for CMV infection. *American Journal of Transplantation* 2008;8(s2):565.
43. **Park JM**, Luan FL. Incidence and risk factors of cytomegalovirus disease in adult kidney or simultaneous pancreas-kidney transplant recipients who received valganciclovir prophylaxis. *American Journal of Transplantation* 2006;6(s2):587.
44. Luan FL, Chopra P, **Park JM**, Norman SP, Cibrik DM, Ojo AK. Efficacy of valganciclovir for the treatment of primary cytomegalovirus infection in renal transplant recipients. *American Journal of Transplantation* 2006;6(s2): 585.

45. Patel MS, Englesbe MJ, **Park JM**, Harmon WE, McDiarmid SV, Magee JC. A cost-benefit analysis of screening, prophylaxis, and monitoring for Epstein-Barr virus to prevent post-transplant lymphoproliferative disorders across pediatric organ transplantation. *American Journal of Transplantation* 2006;6(s2):148.
46. **Park JM**, Arenas JD, Fontana RJ, Lake KD. Efficacy and safety of low-dose valganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients. *American Journal of Transplantation* 2004;4(s8):502.
47. Hardinger KL, **Park JM**, Schnitzler MA, Koch M, Miller BW, Brennan DC. Pharmacokinetics of tacrolimus in kidney transplant recipients: twice daily versus once daily dosing. *American Journal of Transplantation* 2004;4(s8):238.
48. **Park JM**, Calamia JC, Thummel KE, Slattery JT, Carithers Jr. RL, Marsh CL, Hebert MF. CYP 2E1 activity post-orthotopic liver transplantation. *Clinical Pharmacology & Therapeutics* 2002;71:P81.
49. **Park JM**, Larson AM, Carithers Jr. RL, Glue P, Hebert MF. Single-dose and multiple-dose pharmacokinetics of interferon  $\alpha$ -2b in chronic hepatitis C patients. *Pharmacotherapy* 2000;20:1266.
50. **Park JM**, Min DI, Golconda MS, Rayhill SC, Wu Y-M. Efficacy of daclizumab versus muromonab CD3 in preventing acute rejection in kidney and kidney/pancreas transplant recipients at high risk of allograft dysfunction. *Pharmacotherapy* 1999;19:1224.
51. Min DI, **Park JM**, Ku Y-M, Schoenwald R. Effect of grapefruit juice on microemulsion cyclosporine absorption kinetics in healthy volunteers. *Pharmacotherapy* 1998;18:1158.
52. Stanford RH, **Park JM**, Geraets DR, Min DI, Lee H-C. Effect of oral erythromycin on quinidine pharmacokinetics in healthy volunteers. *Pharmacotherapy* 1998;18:426-427.

### **RESEARCH AND SERVICE GRANTS**

1. NIH R01 (PI, Zhu HJ) 9/1/22-8/31/25  
 Title: Carboxylesterase 1 plasma biomarker for precision pharmacotherapy  
 Amount: \$936,000 over 3 years  
 Role: Co-I (8% effort)
2. ACCP IMTR-PRN Research Grant (PI, McMurry KA) 11/1/19-10/31/21  
 Title: Impact of pre-transplant medication education video in kidney transplant recipients  
 Amount: \$5,000  
 Role: Co-I, U-M site PI
3. MICHR Pathways to First Grant Award (PI, Pasternak AL) 3/1/19-9/30/20  
 Title: Determination of a personalized tacrolimus dosing strategy in pediatric renal and heart transplant recipients  
 Amount: \$50,000  
 Role: Co-I (4% effort)

4. Interprofessional Leadership Fellows Seed Funding Award 1/15/19 – 6/30/20  
 - University of Michigan Center for IPE and CRLT  
 Title: Integrating interprofessional education into a first-year undergraduate pre-health learning community  
 Amount: \$5,000  
 Role: Interprofessional Leadership Fellows team project
  
5. The Patient Education Awards Committee (PAEC) at University of Michigan Health 9/9/16 – 9/8/17  
 Title: Kidney Transplant Patient Education Mobile Application  
 Amount: \$3,258  
 Role: Content developer
  
6. University of Michigan M-Cubed 2.0 (Sharma P, **Park JM**, and Sonnenday C) 10/1/15 – 4/29/17  
 Title: Improving Renal Outcomes Among Liver Transplant Recipients  
 Amount: \$15,000  
 Role: Co-PI
  
7. Food & Drug Administration U01 9/10/14 – 2/28/18  
 (PI, Messersmith E, 9/10/14 – 8/3/15; Leichtman A, 8/4/15 – 2/28/18)  
 Title: Transplant outcomes using generic and brand name immunosuppressants: studying medications used by people who have received kidney and liver transplants (1 U01 FD005274-01)  
 Amount: \$965,972 over 2 years (with no cost extension to 2/28/18)  
 Role: Co-I (5% effort for Year 1, 7.5% for Year 2, 5% for Year 3, and 2.5% for Year 4), U-M site PI (5/8/15 – 2/28/18)
  
8. Genzyme Corporation (**PI, Park JM**) 3/1/07 – 12/1/07  
 Investigator-initiated study  
 Title: Efficacy and safety of Thymoglobulin induction in living unrelated renal transplantation  
 Amount: \$12,000 (23% indirect cost)  
 Role: PI (7.5% effort)
  
9. Roche Laboratories, Inc. (**Co-PIs, Park JM** and Lake KD) 8/1/05 – 7/31/07  
 Investigator-initiated study  
 Title: Pharmacokinetics of mycophenolate mofetil alone and in combination with valganciclovir in renal and heart transplant recipients  
 Amount: \$114,425 (20% indirect cost)  
 Role: Co-PI (15% effort)
  
10. National Kidney Foundation of Missouri (PI, Hardinger KL) 2002  
 Title: Pharmacokinetics of tacrolimus in kidney transplant recipients: once daily versus twice daily dosing  
 Amount: \$39,830  
 Role: Co-I



11. Elmer M. Plein Endowed Research Fund (PI, Hebert MF) 2000  
Title: Effects of St. John's wort on cyclosporine and tacrolimus pharmacokinetics in healthy volunteers  
Amount: \$3,000  
Role: Co-I

## **PRESENTATIONS**

### ***Platform/Webinar/Invited Presentations:***

1. Don't "re-search" research: The how-to on leveraging learners, fostering collaboration, and reaching the publication finish line. AST TxPharm COP/ACCP TXP PRN Webinar, July 25, 2024.
2. Lessons Learned from Implementing Standard-of-Care Pharmacogenomic Monitoring. American Transplant Congress 2024, Philadelphia, PA, June 1, 2024.
3. A Role of Transplant Pharmacist. ACCP IMTR PRN Webinar Series, November 7, 2023.
4. A patient's journey to kidney transplant: medications after transplantation. University of Michigan Transplant Center Continuing Education Program for Michigan nurses, social workers, and registered dietitian nutritionists, Ann Arbor, MI, May 19, 2022.
5. Education Innovations in Interprofessional Education: Interprofessional Team Pre-rounds Pilot. RISE Virtual Talking Circles, Ann Arbor, MI, May 16, 2022.
6. Interprofessional Team Pre-rounds Pilot. Pharmacy Grand Rounds at University of Michigan Health, Ann Arbor, MI, June 14, 2021.
7. Therapeutic Strategies for Treating Alcohol Relapse Post-Transplantation. American Transplant Congress 2021 Virtual Connect, June 7, 2021.
8. Immunosuppression in Pediatric Liver Transplantation. Pediatric GI Virtual Conference at University of Michigan Health, Ann Arbor, MI, June 15, 2020.
9. Becoming a Transplant Pharmacist. ACCP IMTR PRN Webinar Series, October 15, 2019.
10. Practical strategies for glucose control and diabetes prevention after liver transplant: where are we now? 2019 American Transplant Congress, Boston, MA, June 2, 2019.
11. Strategies for Clinical Teaching in the Health Sciences. New Faculty Orientation Panel at University of Michigan, Ann Arbor, MI, August 29, 2018.
12. Establishing a new service. ACCP IMTR PRN Webinar Series, September 25, 2017.
13. Critical Thinking in the Clinic. New Faculty Orientation Panel at University of Michigan, Ann Arbor, MI, August 30, 2017.

14. A patient's journey to kidney transplant: medications after transplantation. University of Michigan Transplant Center Continuing Education Program for Michigan nurses, social workers, and registered dietitian nutritionists, Ann Arbor, MI, June 8, 2017.
15. Integrating pharmacy students into your practice: exemplar and best practices. University of Michigan College of Pharmacy Preceptor Education and Recognition Symposium, Ann Arbor, MI, May 12, 2017.
16. ATC TxPharm COP Mentor/Trainee Discussion Panel - Establishing research practices as a new practitioner. 2017 American Transplant Congress, Chicago, IL, May 2, 2017.
17. Management of post-transplant diabetes mellitus. 2017 American Transplant Congress, Chicago, IL, April 30, 2017.
18. Case-based approaches to optimizing transitions of care and patient education. 2016 American Transplant Congress, Boston, MA, June 14, 2016.
19. Making a difference for your transplant patients and interdisciplinary team: understanding immunosuppression. INTERLINK Medical Round Table (webinar for case managers), May 19, 2016.
20. Interprofessional education: what is it, why is it important, and how can I make it happen? University of Michigan College of Pharmacy Preceptor Education and Recognition Symposium, Ann Arbor, MI, May 5, 2016.
21. Careers and education in pharmacy. Health & Biomedical Seminar for Korean American Scientists and Engineers Association-Michigan Chapter (MI KSEA), Ann Arbor, MI, November 18, 2014.
22. Clinical pharmacy practice and education in the United States. College of Pharmacy at Ajou University, Suwon, Korea, October 29, 2014.
23. Evolving role of pharmacists and pharmacy education in the United States. School of Pharmacy at Sungkyunkwan University, Suwon, Korea, October 28, 2014.
24. Making a difference for your transplant patients and interdisciplinary care team. 2014 Fall International Convention of The Pharmaceutical Society of Korea, Gyeongju, Korea, October 23, 2014.
25. Extended-release tacrolimus: considerations in adult kidney and liver transplant. Monday Transplant Center Conference (CME) at University of Michigan Health System, Ann Arbor, MI, September 23, 2013.
26. Cytomegalovirus infection in organ transplant patients. International Transplant Nurses Society-Great Lakes Chapter, Livonia, MI, December 5, 2012.
27. Update on immunosuppression in solid organ transplant. Surgery Critical Care Core Curriculum at University of Michigan Health System, Ann Arbor, MI, October 17, 2012.

28. Update on immunosuppression in solid organ transplant. Surgery Critical Care Core Curriculum at University of Michigan Health System, Ann Arbor, MI, April 18, 2012.
29. Immunosuppression in solid organ transplant. Surgery Critical Care Core Curriculum at University of Michigan Health System, Ann Arbor, MI, February 2, 2011.
30. Overview of immunosuppression. Surgery Critical Care Core Curriculum at University of Michigan Health System, Ann Arbor, MI, April 20, 2010.
31. Update on transplant medications and protocols. Transplant Education Series (Nursing Continuing Education) at University of Michigan Health System, Ann Arbor, MI, April 13, 2010.
32. Overview of immunosuppression. Critical Care Fellow Core Curriculum at University of Michigan Health System, Ann Arbor, MI, April 1, 2009.
33. Overview of immunosuppression. Nursing Education Series at University of Michigan Health System, Ann Arbor, MI, March 19, 2009.
34. Pharmacy practice and education in the United States. Research Institute of Pharmaceutical Sciences at Seoul National University, Seoul, Korea, March 22, 2007.
35. Pharmacotherapy in solid organ transplantation. Graduate School of Pharmacy at Seoul National University, Seoul, Korea, March 22, 2007.
36. Clerkship evaluation: it's more than just forms. University of Michigan College of Pharmacy Preceptor Education and Recognition Symposium, Ann Arbor, MI, June 23, 2006.
37. Immunosuppression and prophylaxis after lung transplantation. Nursing Education Series at University of Michigan Health System, Ann Arbor, MI, May 4, 2006.
38. Medications after transplantation. Spreading Organ Donor Awareness, Flint, MI, May 2, 2005.
39. Transplant pharmacotherapy. Nephrology Fellow Board Review Course at University of Michigan Health System, Ann Arbor, MI, April 5, 2005.
40. Immunology and pharmacotherapy of solid organ transplantation. ACPE-accredited Continuing Education Program, University of Michigan Health System, Ann Arbor, MI August 27, 2003.
41. Pharmacokinetics of cyclosporine. Multidisciplinary Conference for first-year medical students at University of Michigan (Pharmacology 525), Ann Arbor, MI, May 2, 2003.
42. Pharmacotherapy in solid organ transplantation. Critical Care Nursing Continuing Education at University of Michigan Health System, Ann Arbor, MI, March 18, 2003.
43. Management of heparin-induced thrombocytopenia. Missouri Board of Pharmacy-accredited Continuing Education Program, Barnes-Jewish Hospital, St. Louis, MO, May 15, 2002.

44. Efficacy of daclizumab versus muromonab CD3 in preventing acute rejection in kidney and kidney/pancreas transplant recipients at high risk of allograft dysfunction. American College of Clinical Pharmacy Annual Meeting, Kansas City, MO, October 24-27, 1999.

**Poster Presentations:**

1. Chen A, Hagopian J, **Park J**, Walter K, Mreyoud H, Doshi M, Wilpula E. The impact of mycophenolate stewardship on infectious complications in elderly kidney transplant recipients. 2024 American Transplant Congress, Philadelphia, PA, June 1-5, 2024.
2. Walter K, **Park J**, Papaleontiou M, Low Wang C, Gumber R, Choksi P. Utilization of sodium-glucose cotransporter 2 inhibitors in adult kidney transplant recipients: a survey of endocrinology and nephrology provider. 2024 American Transplant Congress, Philadelphia, PA, June 1-5, 2024.
3. Chau MP, Hagopian JC, Marshall VD, **Park JM**. Extended-release tacrolimus and kidney function in *de novo* liver transplant recipients. *American Journal of Transplantation* 2024;24(s6):S966-962024 American Transplant Congress, Philadelphia, PA, June 1-5, 2024.
4. Walter K, Mreyoud H, Wilpula E, **Park J**. A pharmacist survey of utilization of sodium-glucose cotransporter-2 inhibitors in solid organ transplant recipients. 2023 American Transplant Congress, San Diego, CA, June 3-7, 2023.
5. Barakat AO, Harb R, Laviste NC, Ky TQ, Norman S, Taylor R, Smith A, Rassin M, Bergmooser G, **Park JM**. Nurse-managed standardized tacrolimus therapeutic drug monitoring. 2021 Michigan Medicine Quality Month Poster Session (Virtual), October, 2021.
6. Bixby AL, Shaikh SA, Naik AS, Cotiguala L, McMurry K, Samaniego-Picota MD, Marshall VD, **Park JM**. Safety and efficacy of direct-acting oral anticoagulants versus warfarin in kidney transplant recipients. 2020 Virtual American Transplant Congress, May 30-June 1, 2020.
7. Pierce D, Lichvar A, Waldman G, Salerno D, Klem P, **Park J**. Utilization of direct acting oral anticoagulation in solid organ transplant patients: A national survey of institutional practices. 2020 Virtual American Transplant Congress, May 30-June 1, 2020.
8. Sharma P, Tischer S, Kwang H, Sonnenday C, **Park JM**. Post transplant renal outcomes among liver transplant recipients with preserved renal function. Digestive Disease Week 2020, ePoster, May 2, 2020.
9. Pierce D, Lichvar A, Waldman G, Salerno D, Klem P, **Park J**. Utilization of direct acting oral anticoagulation in solid organ transplant patients: A national survey of institutional practices. 2019 American College of Clinical Pharmacy Annual Meeting, New York, NY, October 26-29, 2019. **\*\*Best Resident or Fellow Poster Finalist.**
10. Bixby AL, Fitzgerald L, Cotiguala C, **Park JM**, Kaul D, Sonnenday C, Tischer S. Comparison of two dosing regimens of valganciclovir for cytomegalovirus prophylaxis in high-risk liver transplant recipients. 2019 American Transplant Congress, Boston, MA, June 1-5, 2019.

11. Eickmeyer A, Kattari S, Karl E, Haefner J, **Park J**. Integrating interprofessional education into a first-year undergraduate pre-health learning community. Health Professions Education Day, Ann Arbor, MI, April 2, 2019.
12. Shaikh S, Samaniego M, **Park J**. Direct oral anticoagulation use in kidney transplant recipients. 2018 American Transplant Congress, Seattle, WA, June 2-6, 2018.
13. Lu Y, Lyons J, Tischer S, Woodside K, **Park J**. Efficacy and safety of a single-dose rituximab for prevention of focal segmental glomerulosclerosis recurrence after kidney transplant. 2018 American Transplant Congress, Seattle, WA, June 2-6, 2018.
14. Shaikh S, Panek N, **Park J**. A national survey of valganciclovir dosing strategies in pediatric solid organ transplant recipients. 2018 American Transplant Congress, Seattle, WA, June 2-6, 2018.
15. Leek R, **Park J**, Koerschner C, Mawby J, Wright Nunes J, Sonnenday C, Sharma P. Assessment of a novel chronic kidney disease educational and goal setting tool among liver transplant recipients. 2018 American Transplant Congress, Seattle, WA, June 2-6, 2018.
16. Pasternak AL, Kidwell K, Dempsey J, Sun Y, Hertz DL, **Park JM**. The impact of CYP3A5 genotype on tacrolimus trough concentrations varies between routes of administration. American Society of Clinical Pharmacology and Therapeutics Annual Meeting, Orlando FL, March 21-24, 2018.
17. **Park J**, Koerschner C, Selman S, Mawby J, Paknikar S, Sonnenday C, Wright Nunes J, Sharma P. Knowledge of chronic kidney disease among liver transplant patients. 2017 American Transplant Congress, Chicago, IL, April 29-May 3, 2017.
18. Helmuth M, Turenne M, **Park J**, Liu Q, Oguntimein M, Dutcher S, Balkrishnan R, Zee J, Smith A, Leichtman A. Immunosuppressant costs for Medicare Part D and kidney transplant recipients since the introduction of generic formulations in an incident kidney transplant population. 2017 American Transplant Congress, Chicago, IL, April 29-May 3, 2017.
19. Liu Q, Smith A, **Park J**, Oguntimein M, Dutcher S, Bello G, Helmuth M, Turenne M, Balkrishnan R, Fava M, Sharma P, Beil C, Leichtman A, Zee J. The adoption of generic immunosuppressant medications among kidney and liver transplant recipients using the Colorado all payer claims database. 2017 American Transplant Congress, Chicago, IL, April 29-May 3, 2017.
20. James C, Woodside K, **Park J**, Naik A, Farkash E, Sung R, Samaniego M, Huang Y. Short term renal allograft outcomes following treatment of early subclinical borderline changes on surveillance biopsies. 2017 American Transplant Congress, Chicago, IL, April 29-May 3, 2017.
21. **Park J**, Trofe-Clark J, Kaiser T, Pilch N, Taber D. Association between provision of transplant pharmacy services and center-level patient and graft outcomes in U.S. adult kidney transplant programs. 2017 American Transplant Congress, Chicago, IL, April 29-May 3, 2017.
22. Neal J, Sun Y, Erley J, Shen J, Sonnenday C, Sharma P, **Park JM**. Renal risk index and acute kidney injury in liver transplant patients. 2016 American Transplant Congress, Boston, MA, June 11-15, 2016. **\*\*Poster of Distinction.**

23. Huang Y, **Park JM**, Naik A, Kaul D. Standard dose valganciclovir prophylaxis for high-risk kidney transplant recipients reduces incidences of breakthrough and resistant cytomegalovirus infection. 2016 American Transplant Congress, Boston, MA, June 11-15, 2016.
24. Palumbo A, Kelly L, **Park JM**. Transitions of care to reduce early readmissions following kidney transplantation. American Transplant Congress Annual Meeting, Seattle, WA, May 18-22, 2013.
25. Tischer S, **Park JM**, Sonnenday C, Fontana RJ. Incidence of CMV disease in high-risk liver transplant recipients on low dose valganciclovir prophylaxis. American Transplant Congress Annual Meeting, Seattle, WA, May 18-22, 2013.
26. Gabardi S, Cross R, DePiero K, Dick T, Ferguson K, Newkirk E, **Park JM**, Tichy E, Ueda K, Weng R, Heldenbrand S. Prevention of cytomegalovirus with valganciclovir 450 mg daily vs. 900 mg daily in intermediate risk renal transplant recipients (D-/R+): a multicenter safety and efficacy evaluation. American Transplant Congress Annual Meeting, Seattle, WA, May 18-22, 2013.
27. Stuckey LJ, Ojo TC, **Park JM**, Annesley TM, Bartos CE, Cibrik DM. Pharmacokinetics of mycophenolic acid in cystic fibrosis lung transplant recipients. American Transplant Congress Annual Meeting, Philadelphia, PA, April 30-May 4, 2011.
28. **Park JM**, Figurski MJ, Shaw LM. Valganciclovir does not affect the steady-state pharmacokinetics of mycophenolic acid and its glucuronide metabolites. American Transplant Congress Annual Meeting, Toronto, Canada, May 31-June 4, 2008.
29. Stuckey LJ, **Park JM**, Luan FL. Impact of extended CMV prophylaxis in adult renal transplant recipients at high risk for CMV infection. American Transplant Congress Annual Meeting, Toronto, Canada, May 31-June 4, 2008.
30. **Park JM**, Lake KD, Cibrik DM. Impact of calcineurin inhibitor conversion from cyclosporine to tacrolimus on pharmacokinetics of mycophenolate mofetil in diabetic renal transplant recipients. American College of Clinical Pharmacy Annual Meeting, Denver, CO, October 14-17, 2007.
31. **Park JM**, Figurski MJ, Shaw LM, Lake KD. Valganciclovir does not affect the steady-state pharmacokinetics of mycophenolate mofetil. American College of Clinical Pharmacy Annual Meeting, Denver, CO, October 14-17, 2007.
32. Miller JT, Stuckey LJ, Collins CD, Bauzon C, **Park JM**. Efficacy and safety of rabbit antithymocyte globulin induction in adult living-unrelated renal transplant recipients. American College of Clinical Pharmacy Annual Meeting, Denver, CO, October 14-17, 2007.
33. **Park JM**, Luan FL. Incidence and risk factors of cytomegalovirus disease in adult kidney or simultaneous pancreas-kidney transplant recipients who received valganciclovir prophylaxis. World Transplant Congress, Boston, MA, July 22-27, 2006.
34. Luan FL, Chopra P, **Park JM**, Norman SP, Cibrik DM, Ojo AK. Efficacy of valganciclovir for the treatment of primary cytomegalovirus infection in renal transplant recipients. World Transplant Congress, Boston, MA, July 22-27, 2006.

35. **Park JM**, Arenas JD, Fontana RJ, Lake KD. Efficacy and safety of low-dose valganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients. American Transplant Congress Annual Meeting, Boston, MA, May 15-19, 2004.
36. Hardinger KL, **Park JM**, Schnitzler MA, Koch M, Miller BW, Brennan DC. Pharmacokinetics of tacrolimus in kidney transplant recipients: twice daily versus once daily dosing. American Transplant Congress Annual Meeting, Boston, MA, May 15-19, 2004.
37. **Park JM**, Calamia JC, Thummel KE, Slattery JT, Carithers Jr. RL, Marsh CL, Hebert MF. Cytochrome P450 2E1 activity following orthotopic liver transplantation. American Society of Clinical Pharmacology and Therapeutics Annual Meeting, Atlanta, GA, March 24-27, 2002.
38. **Park JM**, Larson AM, Carithers Jr. RL, Glue P, Hebert MF. Single-dose and multiple-dose pharmacokinetics of interferon  $\alpha$ -2b in chronic hepatitis C patients. American College of Clinical Pharmacy Annual Meeting, Los Angeles, CA, November 5-8, 2000.
39. Min DI, **Park JM**, Ku Y-M, Schoenwald R. Effect of grapefruit juice on microemulsion cyclosporine absorption kinetics in healthy volunteers. American College of Clinical Pharmacy Annual Meeting, Cincinnati, OH, November 8-11, 1998.
40. Stanford RH, **Park JM**, Geraets DR, Min DI, Lee H-C. Effect of oral erythromycin on quinidine pharmacokinetics in healthy volunteers. American College of Clinical Pharmacy Spring Practice and Research Forum, Palm Springs, CA, April 5-8, 1998.

**Conference Organizer/Session Moderator:**

- |           |   |
|-----------|---|
| June 2023 | Session Moderator, American Transplant Congress 2023: Best Practices for Patient Education: Bridging the Equity Gap and Leveraging Technology |
| June 2019 | Session Moderator, American Transplant Congress 2019: Revisiting DOAC Anticoagulation in Transplantation                                      |
| June 2016 | Workshop Moderator, American Transplant Congress 2016: Case-based Approaches to Optimizing Transitions of Care and Patient Education          |

**TEACHING AND MENTORING**

**Course Coordination at University of Michigan College of Pharmacy:**

Academic Year	Term	Course	Credits/term	Students Enrolled
2017-present	W	Therapeutic Problem Solving IV (P712)	3	80
2018-present	SS/F	Pharmacy Student Seminar (P730)	1	80
2007-2018	F/W	Pharmacy Student Seminar (P680, P730)	1	70-90

**Experiential/Didactic Courses at University of Michigan College of Pharmacy:**

Academic Year	Term	Course	Nature of Contribution	Hrs/term	Students Enrolled
2012-present	F/W	Advanced Pharmacy Practice Experience	Preceptor	5 weeks /student	4-6/year
2003-2012	F/W	Advanced Pharmacy Practice Experience	Preceptor	4 weeks /student	6-10/year
2009-2017	F/W	Introductory Pharmacy Practice Experience	Preceptor	Longitudinal	0-4/year
2015-2019	W	Biopharmaceutics and Pharmacogenomics (PS563, PS718)	Instructor/Applied Pharmacokinetics of Tacrolimus	2	80
2013-present	W	Therapeutic Problem Solving IV (P532, P712)	Instructor/Solid Organ Transplant	6-9	80
2004-2005	W	Pathophysiology and Therapeutics IV (P532)	Instructor/Rheumatoid arthritis	3	60
2005-2007	F	Pathophysiology and Therapeutic III (P531)	Instructor/Immunology overview	3	70
2004-2005	W	Pathophysiology and Therapeutics IV (P532)	Instructor/Rheumatoid arthritis	3	60
2003-2004	F	Pathophysiology and Therapeutic III (P531)	Instructor/Solid Organ Transplant	1.5	60
2013	W	EMB/Ethics (P545)	Instructor/Number Needed to Treat	1.5	90
2018-present	SS/F	Pharmacy Student Seminar (P730)	Faculty advisor	Longitudinal	2/year
2004-2018	F/W	Pharmacy Student Seminar (P680, P730)	Faculty advisor	Longitudinal	2/year
2004-present	F/W	PharmD Investigations (P565/P575/P585, P719/P739)	Faculty advisor	Longitudinal	
2013	F	Research Independent Study (P570)	Faculty advisor	Longitudinal	1
2003	W	Pharmaceutical Care IV (P511)	Facilitator/Patient monitoring lab	6	5
2003-2006	F	Pharmaceutical Care III (P510)	Facilitator/Patient monitoring lab	5	5



### ***Ph.D. Dissertation Committees at University of Michigan:***

2021 – present	Sun Min Jung – Clinical Pharmacy Translational Sciences (Zhu lab)
2020 – present	Logan Smith – Clinical Pharmacy Translational Sciences (Zhu lab)
2020 – 2024	Abbie Leino – Clinical Pharmacy Translational Sciences (Pai lab)
2019 – 2023	Jiapeng Li – Clinical Pharmacy Translational Sciences (Zhu lab)

### ***Junior Faculty Mentoring:***

- Azadeh Ali Moghaddam, Pharm.D. (Lecturer, 2024 – present) – Teaching
- Lydia Benitez, Pharm.D. (Clinical Assistant Professor, 2020) – Teaching
- Katie McMurry, Pharm.D. (Transplant Clinical Pharmacist Specialist, 2019 – 2021) – Research
- Amy Pasternak, Pharm.D. (Clinical Assistant Professor, 2017 – 2021) – Research

### ***Postgraduate Training at University of Michigan Health:***

#### 1. PGY2 Transplant Pharmacy Residency

- Alisia Chen, Pharm.D. (2023 – 2024): Transplant Pharmacist, Northwestern University, Chicago, IL
- Hansa Mreyoud, Pharm.D. (2022 – 2023): Transplant Pharmacist, University of Michigan, Ann Arbor, MI; Transplant Pharmacist, Barnes-Jewish Hospital, St. Louis, MO
- Trung Ky, Pharm.D. (2020 – 2021): Transplant Pharmacist, St. Joseph’s Hospital and Medical Center, Phoenix, AZ
- Lauren Schumacher, Pharm.D. (2019 – 2020): Transplant Pharmacist, University of Kentucky HealthCare, Lexington, KY
- Alexandra Bixby, Pharm.D. (2018 – 2019): Transplant Pharmacist, University Hospitals Cleveland Medical Center, Cleveland, OH
- Rachael Simard (Leek), Pharm.D. (2017 – 2018): Transplant Pharmacist, Vanderbilt Health, Nashville, TN
- Suhail Shaikh, Pharm.D. (2016 – 2017): Transplant Pharmacist, MedStar Georgetown University Hospital, Washington, DC; Transplant Pharmacist, University of South California, Los Angeles, CA
- Natalia Jasiak-Panek, Pharm.D. (2014 – 2015): Post-doctoral Fellow, University of Illinois at Chicago, Chicago, IL; Transplant Pharmacist, Ann and Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL
- Catherine Pennington, M.S., Pharm.D. (2013 – 2014): Transplant Pharmacist, Jackson Memorial Hospital, Miami, FL; Transplant Pharmacist, Indiana University Health, Indianapolis, IN
- TrisAnn Rendulic, Pharm.D. (2012 – 2013): Transplant Pharmacist, Henry Ford Hospital, Detroit, MI; Transplant Pharmacist Coordinator and PGY2 Transplant Residency Director, University of Kentucky HealthCare, Lexington, KY

#### 2. Research Project Mentor, PGY1 and PGY2 Pharmacy Residency

- Alisia Chen, Pharm.D. (2023 – 2024)
- Hansa Mreyoud, Pharm.D. (2022 – 2023)
- Abbey Schwery, Pharm.D. (2021 – 2022)
- Annessi Elmasri, Pharm.D. (2021 – 2022)
- Liriany Pimentel, Pharm.D. (2021 – 2022)
- Mina Chau, Pharm.D. (2021 – 2022)
- Jessica Sharkey, Pharm.D. (2020 – 2021)

- Trung Ky, Pharm.D. (2019 – 2021)
  - Lauren Schumacher, Pharm.D. (2019 – 2020)
  - Alexandra Bixby, Pharm.D. (2018 – 2019)
  - Joseph Cusimano, Pharm.D. (2018 – 2019)
  - Rachael Leek, Pharm.D. (2017 – 2018)
  - Joslyn Neal, Pharm.D. (2015 – 2016)
  - Yihan Sun, Pharm.D. (2015 – 2016)
  - Erika Perpich, Pharm.D. (2015 – 2016)
  - Caitlin Early, Pharm.D. (2014 – 2015)
  - Natalia Jasiak-Panek, Pharm.D. (2014 – 2015)
  - Catherine Pennington, M.S., Pharm.D. (2013 – 2014)
  - Emily Israel, Pharm.D. (2012 – 2013)
  - Alison Palumbo, Pharm.D. (2012 – 2013)
  - TrisAnn Rendulic, Pharm.D. (2012 – 2013)
  - Maria Guido, Pharm.D. (2008 – 2009)
  - Sacha Pollard, Pharm.D. (2007 – 2008)
  - Kristen Reaume, Pharm.D. (2007 – 2008)
  - James Miller, Pharm.D. (2006 – 2007)
3. Writing Project Mentor, PGY1 and PGY2 Pharmacy Residency
    - Ashton Strother, Pharm.D. (2023 – 2024)
    - Hansa Mreyoud, Pharm.D. (2022 – 2023)
    - Liriany Pimentel, Pharm.D. (2021 – 2022)
    - Sonya Anderson, Pharm.D. (2019 – 2020)
    - Lauren Schumacher, Pharm.D. (2019 – 2020)
    - Alexandra Bixby, Pharm.D. (2018 – 2019)
    - Catherine Pennington, M.S., Pharm.D. (2013 – 2014)
    - Melissa Carroll, Pharm.D. (2009 – 2010)
    - Loretta Chiu, Pharm.D. (2002 – 2003)
    - Beata Domagala, Pharm.D. (2002 – 2003)
    - William Prescott, Jr., Pharm.D. (2002 – 2003)
  4. Preceptor, Solid Organ Transplantation Rotation
    - PGY1 and PGY2 Pharmacy Residents (2003 – present)
  5. Coordinator, Research Discussion Series for three pharmacy residency programs in the Ann Arbor area (2011 – 2017)
  6. Lecturer, Surgery Critical Care Core Curriculum (annually, 2009 – 2012)
  7. Lecturer, Nephrology Fellow Teaching Conference (annually, 2006 – 2009)
  8. Lecturer, Surgery Transplant Teaching Conference (monthly, 2003 – present)

***Pharmacy Summer Interns at University of Michigan Health:***

1. Supervisor, Transplant Medication Teaching
  - Liz Messana and Silu Zuo (P2, 2012)

- Alex Crowley and Nabeel Qureshi (P2, 2011)
- Salem Kamalay and Claire Walter (P3, 2010)

***Extracurricular Mentorship at University of Michigan:***

1. Pharmacy Phamily at College of Pharmacy (2011 – present)
  - Abigail Hayes (Class of 2027)
  - Marian Fu and Vy Lam (Class of 2026)
  - Zack Kujat (Class of 2024)
  - Dana Ferrand and Jingyu Hu (Class of 2023)
  - Ben Fine (Class of 2022)
  - Erick Leung (Class of 2021)
  - Hannah Hendricks and Amanda Wahab (Class of 2020)
  - Ariel Alber, Brooke Collins, and Si In Long (Class of 2019)
  - Zainab Alsamarrae and Ben Kim (Class of 2018)
  - Katherine Cho and Brian Williams (Class of 2017)
  - Elizabeth Caliman, Meighan LeGrand, Syeda (Maahin) Mahmood, and Darren Najor (Class of 2016)
  - Kallie de Jong and Greg Paige (Class of 2015)
  - Joshua Johnson and Shane Yan (Class of 2014)
2. Rho Chi Shadow Program at College of Pharmacy (2014 – present)
3. Faculty Mentor for Student Organization at College of Pharmacy
  - Student Committee for International Opportunities (2015 – 2017)
4. MICHR Summer Immersion Program
  - Joyce Ting (P2, College of Pharmacy), 2008
5. Transplant Surgery Summer Research
  - David Ranney (Undergraduate, College of Engineering), 2007

***International Programs at University of Michigan:***

1. Advanced Pharmacy Practice Experience (International Exchange)
  - Monica Martinez and Hans Ferrer Yulfo (University of Puerto Rico, January 2017)
  - Cynthia Agosto (University of Puerto Rico, January 2015)
2. Pharmaceutical Care Internship Program (IPSF Exchange)
  - Doshisha Women’s College of Japan (6 students and 1 faculty member, August 2011)
  - University of Kalamoon of Syria (3 students and 1 faculty member, Summer 2008)
  - University of Barcelona of Spain (3 students, Summer 2008)
  - Doshisha Women’s College of Japan (6 students and 1 faculty member, August 2007)
3. Pharmabridge Program (FIP)
  - India (2 faculty members, Summer 2011)
  - India (2 faculty members, Summer 2010)
  - India (2 faculty members, Summer 2008)

#### 4. Others

- University of Montreal of Canada (Co Q.D. Pham, Pharm.D., January 2005)

### **PROFESSIONAL AFFILIATIONS AND SERVICES**

#### ***Membership and Leadership in National Professional Organizations:***

2008 – present

- Member, American Society of Transplantation (AST)
- Coauthor, AST Clinical Practice Recommendations on Induction Immunosuppression in Kidney Transplantation (2023 – present)
  - Panelist and Section Editor, C4 article in American Journal of Transplantation: Challenges and Solutions for Appropriate and Timely Medication Access in Transplantation (2019)
  - Abstract Reviewer for ATC 2018 (2017)
- Member, Transplant Pharmacy Community of Practice (TxPharm CoP)
- Research and Innovation Workgroup (2023 – present)
    - Manuscript Peer Reviewer Guide
    - Research Mentoring Initiative
  - Transplant Pharmacy Adherence Consortium (TPAC) (2018-2019, 2020 – present)
    - Patient Education Videos on Adherence (2023 – present)
    - [Transplant Recipient Adherence Monitoring and Management Tool \(TR-AMMT\)](#) (2021 – 2023)
  - Programming/Education Workgroup (2014 – present)
    - Annual ATC programming proposals
    - Annual ASHP Midyear programming proposals
  - Transplant Reference Collection Workgroup (2014, 2017, 2018)
  - Transplant Pharmacist Workforce Survey Workgroup (2013-2016)

1998 – present

- Member, American College of Clinical Pharmacy (ACCP)
- Member, Transplant Practice Research Network (TXP-PRN)
- TXP-PRN Workforce Committee (2022-2023)
  - TXP-PRN Research Committee (2016-2021)
    - PRN Collaboration Paper, Use of biologics for non-transplant indications in the solid organ transplant population (2021-2022, Co-author)
    - PRN Collaboration Paper, Incorporating pharmacy learners in solid organ transplant services (2020-2021, Co-lead)
    - PRN Collaboration Paper, Transplant stewardship (2020-2021, Co-author)
    - PRN Collaboration Paper, Tacrolimus alternatives (2019-2020, Co-author)
    - PRN Opinion Paper, Comprehensive review of cannabis in solid organ transplant (2018-2020, Co-lead)
    - PRN Opinion Paper, Systematic review of transplant pharmacist research (2016-2020, Co-lead)
    - Chair (2019)
    - Reviewer, TXP-PRN Research Grant applications (2018)
    - Reviewer, TXP-PRN Travel Award (2017)
    - IMTR-PRN Research Grant proposal and launch (2017, Co-lead)

- TXP-PRN Nominations Committee (2017)
    - IMTR-PRN awards proposals (2017)
  - TXP-PRN Secretary-Treasurer (2006-2007)
  - TXP-PRN Educational Programming Committee (2006-2007)
- 1998 – 2003 Member, American Society of Health-System Pharmacists (ASHP)

***Peer Reviewer and Editor for Health Science Journals:***

2023	Reviewer, Expert Review of Clinical Pharmacology
2020 – 2021	Expert Reviewer, ACCP/ASHP Solid Organ Transplantation Pharmacy Review Course
2020 – present	Reviewer, Transplantation
2019 – present	Associate Editor, American Journal of Transplantation
2019 – present	Reviewer, Clinical Transplantation
2019 – present	Reviewer, Liver Transplantation
2019	Reviewer, Journal of Clinical Pharmacy and Therapeutics
2015	Reviewer, Clinical and Experimental Medicine
2014	Chapter Reviewer, Pharmacogenomics in Immunosuppressants in ACCP Pharmacogenomics, 3 <sup>rd</sup> ed.
2010	Case Reviewer, ASHP PharmPrep: Interactive Case-Based Board Review, 4 <sup>th</sup> ed.
2009 – present	Reviewer, American Journal of Transplantation
2009 – 2011, 2020	Reviewer, Pharmacotherapy
2003 – 2004	Guest Editor, Progress in Transplantation (June 2004 issue dedicated on transplant pharmacy)
2000	Reviewer, The Annals of Pharmacotherapy

***External Advisory Board and Consultancy:***

June 2022 – present	External Senior Editor Consultant – Lexicomp Hepatic Dosing Project (Wolters Kluwer)
Jan 22, 2019 – Feb 4, 2019	Global Advisory Board – Dosing and Administration Patterns for T Cell Depletion (Sanofi Genzyme)

**COMMITTEES AND ADMINISTRATIVE SERVICES**

***Interprofessional Education at University of Michigan:***

2022 – present	Member, Intentional Measurement and Research Workgroup – Center for Interprofessional Education
2022 – 2024	Member, Experiential Innovation Workgroup – Center for Interprofessional Education
2020 – present	Member, IPE Executive Committee – Center for Interprofessional Education
2019 – 2022	Chair, Experiential IPE Workgroup – Center for Interprofessional Education
2016	Member, Program Planning Committee for Health Professions Education Day

**University of Michigan College of Pharmacy:**

2023 – present	Member, Curriculum & Assessment Committee <ul style="list-style-type: none"><li>• Curriculum Leadership Team (2023-present)</li><li>• ABO Revision Workgroup (Winter 2024)</li></ul>
2022	Chair, ad hoc Promotion Review Committee for Executive Committee (Clinical Professor without tenure)
2020	Member, Preceptor of the Year Award Selection Committee, Department of Clinical Pharmacy
2019	Member, Search Committee for Research Faculty
2018	Chair, ad hoc Promotion Review Committee for Executive Committee (Clinical Professor without tenure)
2018	Member, ad hoc Promotion Review Committee for Executive Committee (Clinical Professor without tenure)
2017 – 2020	Elected Member, Executive Committee
2017	Member, Search Committee for Clinical Faculty in Pharmacogenomics Implementation, Department of Clinical Pharmacy
2016 – present	Therapeutics Subcommittee for Curriculum & Assessment Committee <ul style="list-style-type: none"><li>• Chair (2022-present)</li><li>• Therapeutics Course Guide Workgroup (2021-2022)</li><li>• Team Skills Workgroup (2019)</li></ul>
2016	Member, ad hoc Promotion Review Committee for Executive Committee (Clinical Associate Professor without tenure)
2014 – 2016	Member, Clinical Skills Subcommittee for Curriculum & Assessment Committee
2013 – 2023	Member, Experiential Education Subcommittee for Curriculum & Assessment Committee <ul style="list-style-type: none"><li>• EPA Workgroup (2021)</li><li>• Steering Committee for MiSPECT – Michigan Supporting Preceptors for Enhanced Clinical Teaching (2019)</li><li>• Development of the Preceptor Credential Survey (2017)</li><li>• Program planning committee and speaker for the Preceptor Education and Recognition Symposium (2016-2018)</li><li>• Preceptor of the Year Award Selection Committee (2014-2018, 2017-Chair)</li></ul>
2012	Member, ad hoc Promotion Review Committee for Executive Committee (Clinical Associate Professor without tenure)
2011 – present	Faculty Interviewer, PharmD Admissions Interviews (4-6 interviews per year)
2011 – 2014	Member, Leadership Committee, Department of Clinical, Social, and Administrative Science
2011 – 2014	Member, ad hoc Educational Outcomes Task Force for Curriculum Committee <ul style="list-style-type: none"><li>• Development of evaluation rubrics for oral and written communication skills</li></ul>
2011 – 2013	Member, Faculty Development Committee <ul style="list-style-type: none"><li>• Teaching Excellence Award Committee (2013)</li><li>• Faculty/Staff Networking Forum (2013)</li></ul>
2010 – 2011	Member, ad hoc EBM Workgroup for Curriculum Committee
2009	Chair, ad hoc Promotion Review Committee for Executive Committee (Clinical Associate Professor without tenure)
2006 – 2007	Member, ad hoc Student Assessment Committee for Experiential Education Committee

- Development of a new evaluation form for student performance during P4 clerkship
  - Program planning committee and speaker for the Preceptor Education and Recognition Symposium (June 2006)
- 2005 Chair, Search Committee for Peripheral Stem Cell Transplant Faculty, Department of Clinical Sciences
- 2004 – 2013 Member, PharmD Investigations Committee (PDI)
- PDI Steering Committee (2013-2015)
- 2003 – 2005 Member, Research Enhancement Committee, Department of Clinical Sciences
- 2003 – 2004 Member, Communications Committee

***University of Michigan Transplant Center:***

- 2022 – present Member, Pediatric Kidney Transplant Length of Stay QI
- 2021 – present Member, Kidney Transplant Shared-Care Improvement Committee
- 2019 Member, Technology Advancement Committee
- 2018 – present Member, Liver Transplant Operating Committee
- 2018 – present Member, Kidney and Pancreas Transplant Steering Committee
- Lead team for Mission/Vision/Values
  - Program strategic priorities
  - Leader-staff huddles
- 2018 Member, Kidney Transplant Adherence Task Force
- 2016 – 2018 Member, Kidney Transplant Education Mobile Application Workgroup
- 2014 – 2018 Member, Liver Transplant Renal-sparing Immunosuppression Workgroup
- 2014 – 2016 Member, Liver Transplant Medication Compliance Task Force
- 2014 – 2016 Member, Kidney Transplant Readmissions Task Force
- Feb 2014 – Sept 2014 Lead, Steering Committee for Transplant Endocrine Clinic
- Nov 2013 – July 2014 Lead Pharmacist, Patient Education Guide Revision for Kidney and Liver
- Sept 2013 – Feb 2014 Lead Pharmacist, Transplant Orderset Validation for MiChart
- 2012 – 2013 Member, Transplant Center Clinic Implementation Project
- 2011 – 2013 Member, Post-Kidney Transplant Management Transformation
- 2006 Chair, Search Committee for Lung Transplant Clinical Pharmacist
- 2002 – present Member, Adult Abdominal Organ Transplant Continuous Quality Improvement Committees (multiple organs)
- 2002 – 2023 Member, Pediatric Abdominal Organ Transplant Continuous Quality Improvement Committees (multiple organs)
- 2002 – 2014 Member, Liver Transplant Policy Committee

***University of Michigan Health Department of Pharmacy Services:***

- 2018 – present 5C-MPLAN Pharmacist
- A3 - STX patient education discharge process (2022 – 2024)
  - Patient portal enrollment (2020)
  - Management of national shortage of generic tacrolimus (2019)
  - Cost savings initiatives: omission of induction for liver transplant and delayed initiation of valganciclovir for CMV prophylaxis (2018)
- 2009, 2011, 2017, 2018 Member, Search Committee for Transplant Clinical Pharmacist

2011 Member, Steering Committee for PGY2-Transplant Specialty Residency Program  
2008 – 2009 Appointed Member, Pharmacy Residency Advisory Committee  
2005 Member, Search Committee for Cardiology Clinical Pharmacist

## **PROFESSIONAL DEVELOPMENT**

DEI and Health Justice Workshops/Seminars – University of Michigan, Ann Arbor, MI

- Race, Ethnicity, and Social Determinants of Health – COP Therapeutics Faculty Retreat (Aug 2022)
- Creating Inclusive Learning Environment – COP Preceptor Education & Recognition Symposium (May 2022)
- Building Toward Belonging: Implicit Bias Training - LARA Compliant (May 2022)
- Creating a College Culture Committed to Equity & Inclusion – COP Faculty & Staff Retreat (May 2022)
- Poverty, Transplant and the Communities We Serve (December 2021)
- Patient Experience 101: Patient Experience, Empathy, and What Matters Most to Patients and Families (April 2021)
- Patient Experience 101: Measurement, Service Recovery, and Reconnecting to Purpose (April 2021)
- Race in Healthcare: Race-Based Drug Recommendations in Cardiology (April 2021)
- Stepping In: Creating a Culture of Respect and Inclusion (March 2021)
- Disparities in Transplantation (December 2020)
- Strategies and Tactics for Recruiting to Improve Diversity and Excellence (STRIDE) (July 2019)
- Disability Awareness and Etiquette (June 2019)
- Changing it Up! (November 2018)
- Diversity Talk: Implicit Bias (July 2018)
- Health literacy and Patient Education ForUM: Needs of transgender people (Feb 2018)
- Health literacy and Patient Education ForUM: Deaf and hard of hearing (HoH) individuals (Sept 2017)

Teaching Workshops – Center for Research on Learning and Teaching (CRLT), University of Michigan, Ann Arbor, MI

- Developing a Plan for Addressing GenAI Writing Tools in Your Classroom This Winter (2023)
- Evidence-based Teaching Practices to Shape Your Response to GenAI Writing Tools (2023)
- Distress Signals: Supporting Students Facing Mental Health Challenges (2018)
- Effective Feedback (2017)
- Therapeutic Problem Solving Retreat (2015)
- Improving your tAPPs for TBL (2014)
- TBL 101 Revisited (2013)
- Team-based Learning Series (2011)
- Writing Effective Multiple Choice Questions (2007, 2013)

Faculty Development Workshops/Seminars – University of Michigan, Ann Arbor, MI

- IPE Learning Community (August 2023-present)
- Microlearning: Impactful Development Conversations (June 2021)
- Create Trust by Asking Questions: The Art of Humble Inquiry (March 2021)
- Healthcare Leadership in Stressful Times (Jan 2021)
- Mid-Career Faculty Symposium (June 2020)



- Cultivating Resilience (June 2020)
- Kick A\$\$ Scientific Presentations (June 2020)
- Productive Conflict (Feb 2020)
- Creating Problem Solvers, Leaders and Coaches workshop series, Level 1: A3 Problem Solving for Clinical Leaders (Nov & Dec 2018)
- Making the Most of Your Presentation (Oct 2016)
- Think Like an Actor, Present Like a Pro (Nov 2015)

Aug 2022	Exam Writing Workshop – COP Faculty Retreat University of Michigan, Ann Arbor, MI
Fall 2020	MICHR Mentoring Academy University of Michigan, Ann Arbor, MI
May 6-8, 2019	ehpic™ – Educating Health Professionals in Interprofessional Care: Advancing the Future of Healthcare through Interprofessional Learning. A Certificate Program for Health Professionals, Educators & Leaders by University of Toronto. University of Michigan, Ann Arbor, MI
Jan 2018 – June 2019	Interprofessional Leadership Fellows program Michigan Center for Interprofessional Education University of Michigan, Ann Arbor, MI
May 7-10, 2018	Train-the-Trainer (T3) Interprofessional Team Development Program University of Washington, Seattle, WA
May 23-25, 2016	Leading Edge: Transforming Experiential Education 2016 AACP Spring Institute, Minneapolis, MN
May 18-20, 2015	Exploring ACPE Standards 2016: Interprofessional, Experiential, and Co-curricular Aspects 2015 AACP Institute, Atlanta, GA
Sept 2014	Diabetes Self-Management Training Workshop Cecilia Sauter, MS, RD, CDE Ambulatory Care Services University of Michigan Health System, Ann Arbor, MI
July 2014	Type I and Type II Diabetes Education Programs Sacha Uelmen, RD, CDE Metabolism, Endocrinology & Diabetes-Domino Farms University of Michigan Health System, Ann Arbor, MI
May 25, 2010	Grant Writers’ Seminar and Workshops: Write Winning Grants David C. Morrison, Ph.D. Michigan Institute for Clinical and Health Research (MICHR) and College of Pharmacy University of Michigan, Ann Arbor, MI

2007 – 2008 Foreign Accent Reduction Program  
Speech Pathology  
University of Michigan Health System, Ann Arbor, MI

Summer 2007 Introductory Course in Clinical Research (INTMED 611)  
Michigan Institute for Clinical and Health Research (MICHHR)  
University of Michigan, Ann Arbor, MI

2001 – 2002 Resident Teaching Workshop Series: Ability-Based Education  
St. Louis College of Pharmacy, St. Louis, MO